Vitamin D Suggested for Children, Seniors, Those With High-Risk Prediabetes
10 Jun 2024
MONDAY, June 10, 2024 -- Empiric vitamin D supplementation is suggested for those aged 1 to 18 years, those older than 75 years, those who are pregnant, and those with high-risk prediabetes, according to an Endocrine Society clinical practice guideline published online June 3 in the Journal of Clinical Endocrinology & Metabolism.
Marie B. Demay, M.D., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues developed clinical guidelines for use of vitamin D to lower the risk for disease among individuals without indications for vitamin D treatment.
The researchers suggest empiric vitamin D supplementation for children aged 1 to 18 years to prevent nutritional rickets and for the potential to reduce the risk for respiratory tract infections; for adults aged 75 years and older due to the potential for reducing mortality risk; for pregnant women due to the potential for reducing the risk for preeclampsia, intrauterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes due to the potential reduction in the risk for progression to diabetes. The optimal doses for empiric vitamin D supplementation remain unclear. The panel suggests supplementation via daily administration of vitamin D for nonpregnant people older than 50 years for whom vitamin D is indicated, and suggests against empiric vitamin D supplementation above the current dietary reference intake to reduce risk among healthy adults younger than 75 years. There was no evidence found to support routine 25-hydroxyvitamin D screening in the general population.
"Healthy populations who may benefit from higher dose vitamin D supplements are those 75 and older, pregnant people, adults with prediabetes, and children and adolescents 18 and younger, but we do not recommend routine testing for vitamin D levels in any of these groups," Demay said in a statement.
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.